21
Participants
Start Date
June 9, 2020
Primary Completion Date
June 30, 2026
Study Completion Date
May 31, 2029
4D-125 IVT Injection
4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.
Observational
Natural History
Columbia University Medical Center/Edward Harkness Eye Institute, New York
Duke University Eye Center/Dept. of Ophthalmology, Durham
Vitreo Retinal Associates, Gainesville
University of Michigan Kellogg Eye Center, Ann Arbor
Retina Foundation of the Southwest, Dallas
University of Colorado, Aurora
University of Utah John A. Moran Eye Center, Salt Lake City
Casey Eye Institute, Oregon Health and Science University, Portland
Lead Sponsor
4D Molecular Therapeutics
INDUSTRY